Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria

British Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2004, Pages 146-152

  Mithwani, Sadik ^a   Aarons, Leon ^b   Kokwaro, Gilbert O ^a   Majid, Oneeb ^b   Muchohi, Simon ^a   Edwards, Geoffrey ^c,d   Mohamed, Sumia ^e   Marsh, Kevin ^a,f   Watkins, William ^c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF KHARTOUM   (Sudan)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Artemether; Children; Intramuscular injection; Malaria; Population pharmacokinetics

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISIN; DIHYDROARTEMISININ;

AFRICA; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MALARIA FALCIPARUM; MALE; MASS SPECTROMETRY; METABOLIC ACIDOSIS; PATIENT SELECTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS;

ACIDOSIS, RESPIRATORY; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; FEMALE; HALF-LIFE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALARIA, FALCIPARUM; MALE; RESPIRATORY INSUFFICIENCY; SESQUITERPENES;

EID: 1242351715     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01986.x     Document Type: Article

References (23)

1. Marsh K, Forster D, Waruiru C et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332: 1399-404.
2. Waller D, Krishna S, Crawley J et al. Clinical features and outcome of severe malaria in Cambian children. Clin Infect Dis 1995; 21: 577-87.
3. Taylor TE, Borgstein A, Molyneux ME. Acid-base status in paediatric Plasmodium falciparum malaria. Q J Med 1993; 86; 99-109.
4. Kildeberg P. Metabolic acidosis in infantile gastroenteritis. Acta Paedtr Scand 1965; 54: 155-67.
5. Murphy SA, Mberu E, Muhia D et al. The disposition of intramuscular artemether in children with cerebral malaria: a preliminary study. Trans R Soc Trop Med Hyg 1997; 91: 331-4.
6. Molyneux ME, Taylor TE, Wirima JJ et al. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71: 441-59.
7. Newton CR, Chokwe T, Schellenberg JA et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91: 161-5.
8. Winstanley P, Newton C, Watkins W et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Trans R Soc Trop Med Hyg 1993; 87: 201-6.
9. Newton CR, Kirkham FJ, Winstanley PA et al. Intracranial pressure in African children with cerebral malaria. Lancet 1991; 337: 573-6.
10. English M, Waruiru C, Marsh K. Transfusion for respiratory distress in life-threatening childhood malaria. Am J Trop Med Hyg 1996; 55: 525-30.
11. English M, Waruiru C, Amukoye E et al. Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. Am J Trop Med Hyg 1996; 55: 521-4.
12. Mohamed SS, Khalid SA, Ward SA et al. Simultaneous determination of artemether and its major metabolite dihydroartemisinin in plasma by gas chromatography-mass spectrometry-selected ion monitoring. J Chromatogr B Biomed Sci Appl 1999; 731: 251-60.
13. Altman D, Machin D, Bryant T, Gardner MJ. Statistics with confidence, 2nd edn. Bristol: BMJ Books, 2000.
14. Beal S, Boeckman A, Sheiner L. NONMEM user's guide, Parts I-IV. San Francisco: University of California, 1998.
15. Karbwang J, Na-Bangchang K, Congpuong K et al. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur J Clin Pharmacol 1997; 52: 307-10.
16. Colussi D, Parisot C, Legay F et al. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci 1999; 9: 9-16.
17. Lefevre G, Carpenter P, Souppart C et al. Pharmacokinetics and electrocardiographic pharmacodynamics of artemetherlumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002; 54: 485-92.
18. Alin M, Bjorkman A, Ashton M. In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1990; 84: 635-7.
19. Murphy S, Watkins WM, Bray PG et al. Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Am J Trop Med Hyg 1995; 53: 303-5.
20. Teja-Isavadharm P, Nosten F, Kyle DE et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol 1996; 42: 599-604.
21. Murphy S, English M, Waruiru C et al. An open randomised trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans R Soc Trop Med Hyg 1996; 90: 298-301.
22. McIntosh H, Olliaro P. Artemisinin derivatives for the treatment of malaria (Cochrane Review). The Cochrane, Issue I. Oxford: 2003.
23. Ilett KF, Batty KT, Powell SM et al. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol 2002; 53: 23-30.